Skip to main content

Long-Read Sequencing

Long-Read Sequencing

Long-read sequencing is an advanced DNA and RNA sequencing approach that generates reads typically ranging from several kilobases to over 100 kilobases in length. Unlike short-read technologies, long-read sequencing enables accurate resolution of repetitive regions, structural variants, haplotypes, and complex genomic rearrangements. This technology has transformed genome assembly, transcriptome profiling, and epigenetic analysis by providing more contiguous and biologically informative sequences. Major long-read sequencing platforms include Pacific Biosciences (SMRT sequencing) and Oxford Nanopore Technologies, both of which allow real-time, single-molecule sequencing without PCR amplification. Long-read sequencing is increasingly applied in clinical genomics, cancer research, and population studies.

Long-Read Sequencing Single-Molecule Sequencing Genome Assembly Structural Variant Detection Haplotype Phasing Epigenetic Analysis Transcriptomics PacBio SMRT Sequencing Nanopore Sequencing Advanced Genomics

#LongReadSequencing#Genomics#DNASequencing#SingleMoleculeSequencing#StructuralVariants#GenomeAssembly#Transcriptomics#PrecisionMedicine#BiomedicalResearch

International Conference on Genetics and Genomics of Diseases 

Visit: genetics-conferences.healthcarek.com

Award Nomination: genetics-conferences.healthcarek.com/award-nomination/?ecategory=Awards&rcategory=Awardee

Award registration: genetics-conferences.healthcarek.com/award-registration/ 

For Enquiries: support@healthcarek.com 

Get Connected Here 
--------------------------------- 
--------------------------------- 
in.pinterest.com/Dorita0211 
twitter.com/Dorita_02_11_ 
facebook.com
linkedin.com/in/genetics-r/profile.php?id=61555903296992 

instagram.com/p/C4ukfcOsK36 
genetics-awards.blogspot.com/

Comments

Post a Comment

Popular posts from this blog

Genetic factors with clinical trial stoppage

Genetic factors associated with reasons for clinical trial stoppage Many drug discovery projects are started but few progress fully through clinical trials to approval. Previous work has shown that human genetics support for the therapeutic hypothesis increases the chance of trial progression. Here, we applied natural language processing to classify the free-text reasons for 28,561 clinical trials that stopped before their endpoints were met. We then evaluated these classes in light of the underlying evidence for the therapeutic hypothesis and target properties. We found that trials are more likely to stop because of a lack of efficacy in the absence of strong genetic evidence from human populations or genetically modified animal models. Furthermore, certain trials are more likely to stop for safety reasons if the drug target gene is highly constrained in human populations and if the gene is broadly expressed across tissues. These results support the growing use of human genetics to ...
Post a Comment
Read more

Post-Stroke Cardiovascular risks

Study finds genetic factors key to post-stroke cardiovascular risks In a recent study published in the journal Stroke , researchers identify genetic and molecular risk factors for subsequent cardiovascular outcomes after incident stroke in an effort to identify potential therapeutic targets to improve patient prognoses. Identifying the causes of stroke Stroke is a major global health issue that causes significant disability and mortality, particularly arterial ischemic stroke (AIS). AIS, which is a type of stroke caused by blocked blood flow to the brain, is responsible for up to 85% of stroke cases. AIS arises due to cerebral blood vessel blockage, with modifiable risk factors including hypertension, diabetes, dyslipidemia, atrial fibrillation, obesity, and lifestyle behaviors. Although genome-wide association studies (GWAS) often focus on incident strokes, studying subsequent events can provide new insights into stroke progression. Further research is crucial to identify genetic and...
Post a Comment
Read more

Type of Inherited Blindness in Dogs

Genetic test could eradicate a type of inherited blindness in dogs A mountain rescue dog whose duties ended after her eyesight failed has helped scientists create a test that could eradicate the genetic eye condition in her breed for good. Shola the English shepherd has an inherited eye disease called progressive retinal atrophy (PRA) that causes the light-sensitive cells at the back of the eye to deteriorate, eventually leading to blindness. PRA affects more than 100 dog breeds, can be caused by a number of different genetic variants and has no treatment. For some types, symptoms do not appear until the dog is several years old , by which point they may have passed their genes on to puppies. Katherine Stanbury, the first author of the research from the University of Cambridge, said Shola was four years old when she began struggling with her vision in dim light. “She was sent to a veterinary ophthalmologist and they confirmed that she had PRA,” said Stanbury. “And then it turned out h...
Post a Comment
Read more